Skip to content
Company Analysis

Cyclo Therapeutics, Inc. CYTHW

A comprehensive view of key metrics, scores, and financial health for Cyclo Therapeutics, Inc.

Overview of Cyclo Therapeutics, Inc.

CYTHW NCM
Healthcare Drug Manufacturers - Specialty & Generic
Cyclo Therapeutics, Inc. (CYTHW), in the Drug Manufacturers - Specialty & Generic industry.
-
-
Previous close
Enterprise Value
-
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Fair
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Fair
Updated: Mar 8
Top Beats

Quick Facts

Website https://cyclotherapeutics.com
HQ Gainesville, FL
Employees 8
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data
Show more details
  • Shares outstanding missing or non-positive

Engine Room Money Flow™

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$1.1M
Gross Profit
$977.9K
140.6%%
R&D Expense
$14.2M
Operating Income (EBIT)
$-20.1M
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
1317.5%
Fair

High R&D intensity - heavy pipeline investment

Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
Analysis based on partial data. Some metrics unavailable for complete assessment.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Cyclo Therapeutics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
22
/100
Weak
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
35
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 64% Coverage
Trade-Off Triangle Visualization A ternary plot showing CYTHW's balance between Growth (32.3%), Profitability (19.2%), and Safety (48.5%). Growth 32% Safety 48% Profitability 19%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

26th percentile vs peers
27
Key Signals
Rev Growth YoY 0.0% 34p Revenue CAGR 3Y -12.1% 17p
Strengths
  • Gross Profit Margin in top 20% of peers (90.8%, 90th percentile)
Risks

No significant risks identified for this axis.

Profitability

15th percentile vs peers
16
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

39th percentile vs peers
40
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Cyclo Therapeutics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info